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More than ever, malaria is one of the most threatening tropical diseases and causes inexpressible suffering in more than 90 countries. Official estimates range between 1.5 million and 2.7 million fatal eases and between 300 million and 500 million clinical cases of malaria per year, and these are accom panied by considerable socioeconomic damage (18, 49). Con trol of the disease is, among other factors, hampered by resistance of the vector {Anopheles spp.) to insecticides and an ongoing spread o f drug-resistant strains of Plasmodium falciparum, the malaria parasite most dangerous to humans. Resistance to chloroquine has becom e very common not only in Southeast Asia but also in considerable parts of Africa, South America, and Oceania. At present, there is no country in sub-Saharan Africa from which chloroquine re sistance has not been reported (1, 38) . Multidrug resistance increases in intensity and spreads geographically. In South east Asia and, more specifically, in the border regions be tween Thailand and both Myanmar (Burma) and Cambodia, P. falciparum has developed resistance to all commonly available antimalarial drugs (16, 28, 32, 39, 47, 48) . In ad dition, the emerging resistance o f Plasmodium vivax to a variety o f drugs has been reported (35, 36, 41) . On the basis o f th ese facts, it is obvious that new antimalarial agents are u rgen tly needed (37) .
Extracts from species of the families Dioncophyllaceae and Ancistrocladaceae (6), tropical lianas containing naphthyliso quinoline alkaloids, a new class of natural products with special structural and biosynthetic characteristics (3, 5, 10), have been w idely applied in traditional medicine of several African and A sian countries. Dioncophyllum thollonii (Dioncophyllaceae) is know n for its activity against leprous skin disease (31), Ancistrocladus abbreviatus (Ancistrocladaceae) is known for its activ ity against measles and fevers (27) , and Ancistrocladus tectorius is known for its activity against dysentery and malaria (43).
Several extracts from such species and naphthylisoquinoline alkaloids derived therefrom, as well as synthetic mono-and dim eric alkaloids, exhibit a variety of biological activities (10). T h e y are especially active against asexual erythrocytic stages o f P. falciparum N F 54 and K.1 and Plasmodium berghei
A n k a in vitro (2, 11-13, 20-23, 25, 26). These intracellular sta g es are of particular interest, being responsible for all clinical malaria symptoms (46). Besides, the potential of naph thylisoquinoline alkaloids against exocrythrocytic stages of P. berghei in human hepatoma cells has recently been demon strated (24, 26), These results, combined with the low cytotox icity o f the compounds (23), make them candidates for in vivo testing. The availability of a selection of alkaloids permitted experim ents on their antimalarial activities in P. berghei-infeeted rodents (30, 34) as part of the preelinieal phase of their The pumps were implanted subcutaneously in the backs of C57Black/6J mice at day -1 , and all mice were inoculated intraperitoneally with 10ft P. bettfhei K173 parasites at day 0. The level of parasitemia was determined as described above. The »surviving mice were sacrificed at day 28 after infection.
MATERIALS AND METHODS
The absence of circulating parasites in treated, smear-negative C57Blaek/(U mice was verified at day 14 after infection by the transfer of 0.1 ml of blood into naive Swiss mice that were examined for the development of parasitemia for a 4-week period. 
Treatment

Control Dioncophylline A Dioncophylline B Dioncophylline C D ioncopeltine A
Dioncophylline B (2)
HO OCH3 Table 1 ). The CH2Cl2-NH3 stem bark extract from T. peltatum suppressed the parasitemia significantly (day 4), while the other four extracts were inactive. Several pure naphthylisoquinoline alkaloids from T. peltatum were highly active ( Table 2 ). Dioncophylline B and dioneopcltine A sup pressed the parasitemia significantly (47 and 99% at day 4, respectively), while dioncophylline C was the most active compound tested and com pletely clcared the parasites from the peripheral blood. Dioncophylline A had no effect ( Administration of dioncophylline C at dosages ranging from .125 to 100 mg kg 1 day to P. berghei-infected mice by the 4-day test revealed significant inhibitory activities at 12.5 mg kg 1 day 1 and higher dosages ( Table 3 ). The calculated EDs (with their corresponding 95% confidence intervals given in parentheses) at day 4 are as follows: 25% ED (E D 25), 6.81 mg kg"1 day""1 (5.48 to 8.46 mg kg'"1 day'"'); ED iu, 10.71 mg kg 1 day" 1, (8.94 to 12.83 mg kg"'1 d ay1 ) ; and E D t,s, 32.44 mg kg~1 day" 1 (23.40 to 44.98 mg kg" 1 day '). The effective range for oral application of dioncophylline C is 12,5 to 50 mg kg 1 day-1 , since dosages below 12.5 mg kg 1 day 1 did not sup press proliferation of the parasite and 100 mg kg 1 day 1 caused a mild but transient neurotoxic effect in one of six treated mice. The initial reduction of the parasitemia by ages of 12.5 and 25 mg kg 1 day 1 up to day 4 was not sufficient to prolong the mean survival limes of the animals, in contrast to the complete cure caused by 50 and 100 mg kg 1 day"'1. No obvious acute or chronic side effects could be noted in OF1 mice treated with four dosages of 50 mg kg 1 day l. They looked normal and behaved absolutely normally during several months of observation after the treatment.
RESULTS
P. berghei-infected O F l mice were orally treated with three extracts from T. peltatum and two extracts from A. abbreviatus in the 4-day test (
Administration of a single dosage of 50 mg of dioncophylline C kg 1 day 1 at day 0 suppressed the parasitemia by 99.6% until day 4 postinfection, but four daily treatments were re quired for complete cure ( Table 4 ). The proportion of mice that cleared the parasitemia increased with the number of daily applications: none of six, two of six, and five of six mice after one, two, and three applications, respectively, indicating a strict linear dose-response relationship (r = 0.984) and result ing in 2.38 daily treatments to cure 50% of the mice.
Dioncophylline C was also administered via other routes by using the 4-day schedule. Both the subcutaneous and intrave nous routes were proven to be effective, although the effects were not strong enough to persist until day 7. Subcutaneous application of 20 mg kg"1 clay '1 reduced the level of para sitemia by ca. 84% (P < 0.001) at day 4, while dosages of 5 and 1.25 mg kg 1 day.1 had no effect. These results are compara ble to those obtained after oral administration of dioncophyl line C (Table 3 ). Intravenous injection of the compound was more effective, since dosages of 20, 5, and 1.25 mg kg 1 day 1 suppressed the parasitemia at day 4 by 89% (P < 0,0001), 38%' . peltatum (dioncophyllines B and C and dioncopeltine A) for the resistant line (dioncophylline C, 87% at day 4; dioncopel-P. falciparum and P. berghei in vitro were far below 1 (Jig/ml, tine A, 72% at day 4), and complete cure was not obtained in the 4-day regimen. (20, 22, 23) . Again, the compounds Sustained administration of both dioncophylline C and di-with the highest in vitro activities were by far the m ost effective oncopeltine A to C57Black/6J mice was obtained via subcutaneously implanted mini-osmotic pumps ( Table 7) . A daily dose ones in vivo, as shown in the cases of dioncophyllines B and C and dioncopeltine A ( Table 2 ). The best in vivo results were obtained by treatment with dioncophylline C (IC5()s, 0.014 and confirmed by isodiagnosis with Swiss mice. Very low levels of 0.015 (xg/ml for blood forms of P. falciparum and P. berghei in parasitemia (<l%) were determined in some of the mice at vitro, respectively) of P. berghei-infected O Fl mice, causing a of 20 mg kg 1 resulted in both cases in a rapid and radical cure days 5 and 6 during the dioncopeltine A treatment but only at day 5 during the dioncophylline C treatment.
while the corresponding value for dioncophylline A was about 1 jxg/ml in both systems
complete clearance of parasites after oral administration of 50 mg kg 1 day 1 ( 0.01 (0.00-0.02) 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.00) " Mice were orally treated with 50 mg of dioncophylline C kg "1 day h Parasitemia levels were determined prior to the next treatment. Vi v Probability level of difference with control values. '' Not significantly different from control in one-way ANOVA. ''Significantly different from controls in one-way ANOVA. There is a good correlation between the suppression of par asitemia of P. berghei Anka-infected OFl mice and the dose of dioncophylline C administered in the 4-day test ( Table 3 ). The
4-day schedule used for dioncophylline C is comparable to the chloroquine treatment scheme required to cure P. berghei Anka-infected O Fl mice (data not shown). A minimum num-
C kg "1 day-1 was needed to cure all P. berghei-infected OFl mice (Table 4 ). It is encouraging (Table 4 and data not shown) that one oral treatment reduced the level of parasitemia by 99.6% and produced 50% smear-negative mice at day 4.
The effects of dioncophylline C depend on the pharmacoki netic properties and bioavailability of the compound in the bloodstream. The difference in efficacy between the oral and subcutaneous route on the one hand and the intravenous route on the other hand could relate to chemical instability, limited absorption, a rapid metabolization in the gastrointestinal tract after oral administration, or the appearance of peak levels after intravenous application.
The strong effects of dioncophylline C administered to OFl mice starting 3 days after the infection (Table 5 ) suggest that less than five daily treatments could be considered sufficient to cure mice with established malaria infections. The somewhat lower activities of both dioncophylline C and dioncopeltine A against the chloroquine-resistant P. berghei Anka CRS strain ( Table 6 ) could possibly be improved in adapted administra tion schemes as well.
The most effective treatments with dioncophylline C and dioncopeltine A were obtained with subcutaneously implanted osmotic pumps, which allowed for the sustained release of the drugs at a rate of 1 |xl/h ( Table 7 ). The high efficacy obtained with osmotic pumps suggests the importance of these and other sustained-release systems for the delivery of naphth ylisoquinoline alkaloids in future experiments and applica tions.
The considerable potential of the naphthylisoquinoline al kaloids as new antimalarial drugs, already strongly suggested by data obtained previously from in vitro experiments with P. falciparum and P. berghei (20, 22, 23) , was confirmed by these results. Dioncophyllines B and C and dioncopeltine A are highly active against the rodent malaria parasite P. berghei in vivo, and in particular, dioncophylline C is a promising candidate for further development in the preclinical and clin ical phases. On the other hand, many more naphthylisoquino line alkaloids of natural and synthetic origin are waiting for further evaluation in the in vitro and in vivo malaria models. These new tools for the chemotherapy of malaria are badly needed, considering the deteriorating global malaria situation, 
